#USA #New Haven #Trevi Therapeutics #Haduvio #chronic cough

Trevi Therapeutics: Commitment to Innovation in Respiratory Care

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is making headlines as it prepares to participate in a series of influential investor conferences this February. The clinical-stage biopharmaceutical firm is showcasing its ongoing development of Haduvio™, an oral formulation of nalbuphine extended-release, aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Upcoming Conferences

Trevi will be represented by its senior management team at three significant investor gatherings:

1. Piper Sandler Biopharma Mogul Summit
Dates: February 2-4, 2025
Location: Park City, Utah
Representative: Lisa Delfini, Chief Financial Officer

2. Oppenheimer Healthcare 2025 Winter CEO Investor Summit
Dates: February 3-6, 2025
Location: Vail, Colorado
Representative: Jennifer Good, President and CEO

3. Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Dates: February 11-12, 2025
Corporate Presentation: February 11, 9:20 - 9:50 AM ET
Representatives: Jennifer Good, President and CEO, and James Cassella, Chief Development Officer

Investors interested in the corporate presentation can register to view it live.

The Unmet Need for Chronic Cough Management

Chronic cough is a significant and disruptive condition affecting patients with IPF, with estimates suggesting that about 85% of this patient population experiences chronic cough. The frequency of coughing can be extreme, with some individuals reporting up to 1,500 episodes per day. This condition not only adds to the physical burden of the disease but can also deteriorate patients' social interactions and mental well-being, leading to decreased quality of life and increased risk of mortality.

Currently, there are no FDA-approved therapies specifically for chronic cough in IPF, and the off-label options provide limited relief. Trevi’s Haduvio aims to address this critical gap in treatment.

Understanding Haduvio

Haduvio is designed to target the cough reflex through a dual mechanism. It functions as a kappa agonist and a mu antagonist (KAMA), addressing the central and peripheral aspects of cough hypersensitivity—a key element in conditions like IPF and RCC. With a considerable population affected by refractory chronic cough, estimated between 2 to 3 million adults in the U.S., the need for effective treatment options is urgent.

Refractory chronic cough can lead to a range of complications, causing severe disruptions in daily life including sleep disturbances, urinary incontinence, and social embarrassment. Despite its significant impact, there is no approved treatment for RCC in the U.S., thus highlighting the potential importance of Haduvio in improving patient outcomes.

The Path Ahead

As Trevi prepares for these conferences, it exemplifies a commitment to addressing the unmet medical needs of chronic cough sufferers. The firm's innovative approach with Haduvio promises to bring hope to those seeking relief from their persistent cough, while the presence at these investor conferences underscores its dedication to transparency and engagement with the investment community.

For further updates and to learn more about their developing therapies, interested parties can follow Trevi Therapeutics on social media platforms, including X (formerly Twitter) and LinkedIn, or visit their official website at TreviTherapeutics.com.

Conclusion

Trevi Therapeutics is on the verge of potentially changing the landscape for chronic cough management. With its active participation in upcoming investor conferences, the company is setting the stage for potential breakthroughs in treatment that could significantly enhance the quality of life for many individuals battling chronic cough.